Moolec Science (MLEC) Change in Intangibles (2023 - 2024)
Moolec Science (MLEC) reported Change in Intangibles of -$284372.0 for Q4 2024, down 29.36% on a YoY basis from -$402568.2 in Q1 2024, and down 29.36% sequentially from -$219829.0 in Q4 2023.
Moolec Science (MLEC) Change in Intangibles (2023 - 2024) Analysis & Trends
Moolec Science (MLEC) has 2 years of Change in Intangibles data on file, last reported at -$284372.0 in Q4 2024.
- For the quarter ending Q4 2024, Change in Intangibles fell 29.36% year-over-year to -$284372.0; the trailing twelve-month figure through Dec 2024 stood at -$602159.0 (changed N/A YoY), and the FY2024 full-year result was -$1.1 million, down 591.81% from the prior year.
- Change in Intangibles retreated to -$284372.0 in Q4 2024, from -$219829.0 in the prior quarter.
- In the past five years, Change in Intangibles ranged from a high of -$18184.0 in Q2 2023 to a low of -$284372.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -66,508.31 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Moolec Science | 5.21 Bn | 5.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -284,372.00 |
| Dec 31, 2024 | -284,372.00 |
| Dec 31, 2023 | -219,829.00 |
| Dec 31, 2023 | -219,829.00 |
| Jun 30, 2023 | -18,184.00 |
| Jun 30, 2023 | -18,184.00 |
| Mar 31, 2023 | -79,774.00 |
| Mar 31, 2023 | -79,774.00 |